| P50 | author | Laura B Ramsey | Q42187542 |
| | Mary V Relling | Q88331217 |
| P2093 | author name string | William E Evans | |
| | Cheng Cheng | |
| | Charles J Sherr | |
| | Richard T Williams | |
| | Laura J Janke | |
| | Mathew J Edick | |
| P2860 | cites work | Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia | Q24622397 |
| | Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing | Q24632749 |
| | Treating childhood acute lymphoblastic leukemia without cranial irradiation | Q24644599 |
| | Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations | Q27820693 |
| | Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia | Q28943431 |
| | Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization | Q29614701 |
| | Dose translation from animal to human studies revisited | Q29618049 |
| | Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF | Q29619663 |
| | Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine | Q33336860 |
| | Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia | Q33624061 |
| | Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus | Q33882066 |
| | Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism | Q34429411 |
| | Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia | Q34546468 |
| | Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine | Q34755513 |
| | Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group | Q34992080 |
| | Germline genetic variation and treatment response on CCG-1891. | Q35190653 |
| | Substrain-specific differences in survival and osteonecrosis incidence in a mouse model | Q36481285 |
| | The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia | Q36908947 |
| | The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias | Q37333312 |
| | Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study | Q37502607 |
| | A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday | Q41821365 |
| | Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia | Q42381521 |
| | A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group). | Q42630783 |
| | Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. | Q42826829 |
| | Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia | Q43221788 |
| | DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma | Q43231309 |
| | Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism | Q44097585 |
| | Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia | Q44917795 |
| | Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. | Q45964819 |
| | Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia | Q46398603 |
| | Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes | Q46616526 |
| | Thiopurine methyltransferase in acute lymphoblastic leukemia | Q46886254 |
| | High incidence of secondary brain tumours after radiotherapy and antimetabolites. | Q48163138 |
| | Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. | Q52579212 |
| | Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia | Q68092294 |
| | Long-term culture of murine bone marrow precursors of B lymphocytes | Q68836279 |
| | Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency | Q74337520 |
| P433 | issue | 5 | |
| P921 | main subject | mercaptopurine | Q418529 |
| | murine model | Q122890741 |
| P304 | page(s) | 263-271 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | Pharmacogenetics and Genomics | Q10534561 |
| P1476 | title | Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model | |
| P478 | volume | 24 | |